Synchronous Thyroid and Gastric Mantle Cell Lymphoma
Kmira Zahra *
Department of Clinical Hematology, University Hospital Farhat Hached, Sousse 4000, Tunisia.
Rania Bouneb
Department of Intensive Care, University Hospital Farhat Hached, Sousse 4000, Tunisia.
Sarra Mestiri
Department of Pathology, University Hospital Farhat Hached, Sousse 4000, Tunisia.
Mohamed Mahjoub
Department of Hospital Hygiene Unit, University Hospital Farhat Hached, Sousse 4000, Tunisia.
Monia Zaier
Department of Clinical Hematology, University Hospital Farhat Hached, Sousse 4000, Tunisia.
Yosra Ben Youssef
Department of Clinical Hematology, University Hospital Farhat Hached, Sousse 4000, Tunisia.
Abderrahim Khelif
Department of Clinical Hematology, University Hospital Farhat Hached, Sousse 4000, Tunisia.
*Author to whom correspondence should be addressed.
Abstract
Introduction: Mantle cell lymphoma (MCL) is a distinct entity within the World Health Organization classification of lymphoid neoplasm and represents approximately 8% of lymphoma. Patients with mantle-cell lymphoma typically present with extensive disease and involvement of multiple lymph nodes as well as the spleen, bone marrow, blood, and gastrointestinal tract. MCL of the thyroid occurs exceptionally. The MCL of the stomach is also an exceptional occurrence.
Observation: We describe the case of a 58-year-old male who was diagnosed with thyroid and gastric MCL. The patient was classified into high risk group according to the Mantle Cell Lymphoma International Prognostic Index (MIPI). The R-CHOP (Rituximab, Cyclophosphamide, Adriablastine, Vincristine and Prednisone) regimen was started and complete remission was achieved after 8 courses. He currently receives a maintenance treatment with rituximab every two months.
Conclusion: This case is a combination of two rather infrequent extranodal localizations of the MCL.
Keywords: Mantle cell lymphoma, thyroid, stomach, chemotherapy